title: Does message framing predict willingness to participate in a hypothetical HIV vaccine trial: an application of Prospect Theory.
abstract: It is vital that enough participants are willing to participate in clinical trials to test HIV vaccines adequately. It is, therefore, necessary to explore what affects peoples' willingness to participate (WTP) in such trials. Studies have only examined individual factors associated with WTP and not the effect of messages about trial participation on potential participants (e.g., whether losses or gains are emphasized, or whether the outcome is certain or uncertain). This study explores whether the effects of message framing on WTP in a hypothetical HIV vaccine trial are consistent with Prospect Theory. This theory suggests that people are fundamentally risk averse and that (1) under conditions of low risk and high certainty, gain-framed messages will be influential (2) under conditions of high risk and low certainty, loss-framed messages will be influential. This cross-sectional study recruited 283 HIV-negative students from a South African university who were given a questionnaire that contained matched certain gain-framed, certain loss-framed, uncertain gain-framed, and uncertain loss-framed statements based on common barriers and facilitators of WTP. Participants were asked to rate how likely each statement was to result in their participation in a hypothetical preventative HIV vaccine trial. Consistent with Prospect Theory predictions, for certain outcomes, gain-framed messages were more likely to result in WTP than loss-framed messages. Inconsistent with predictions, loss-framed message were not more likely to be related to WTP for uncertain outcomes than gain-framed messages. Older students were less likely to express their WTP across the different message frames. Recruitment for HIV vaccine trials should pay attention to how messages about the trial are presented to potential participants.
authors.affiliation: Department of Psychology, Royal Holloway University of London, London, UK. michael.evangeli@rhul.ac.uk
authors.forename: Michael
authors.initials: M
authors.lastname: Evangeli
authors.forename: Zuhayr
authors.initials: Z
authors.lastname: Kafaar
authors.forename: Ashraf
authors.initials: A
authors.lastname: Kagee
authors.forename: Leslie
authors.initials: L
authors.lastname: Swartz
authors.forename: Philippa
authors.initials: P
authors.lastname: Bullemor-Day
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D000293:Adolescent; D002986:Clinical Trials as Topic / Q000379:methods* / Q000523:psychology; D003142:Communication; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000523:psychology; D006801:Humans; D008297:Male; D008960:Models, Psychological; D018579:Patient Selection; D012307:Risk Factors; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines